Excess menstrual bleeding and its treatment with Purslane seeds and Tranexamic acid

A comparative clinical study of Tuqme Khurfa(Portulaca oleracea) versus Tranexamic acid in Heavy Menstrual Bleeding - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/107050

Enrollment

Registered

2026-03-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N924- Excessive bleeding in the premenopausal period

Interventions

Intervention1: Group A: Test Drug-Tuqme Khurfa-Purslane seeds (Portulaca oleracea): Patients of Group A will be given 6 grams of Purslane seeds powder(capsule form) in three divided doses per day for

Eligibility

Inclusion criteria

Inclusion criteria: Participants within age group 40 to 50 years (Both Married and Unmarried) With Regular Menstrual cycles (21 to 35 days) With prolonged bleeding greater than 8 days With PBAC (Pictorial Blood Loss Assessment Chart) Score greater than 100 With both prolonged bleeding greater than 8 days and PBAC (Pictorial Blood Loss Assessment Chart) Score greater than 100

Exclusion criteria

Exclusion criteria: Post menopausal bleeding Leiomyomas Cervical lesions Systemic illness Uncontrolled Hypothyroidism Coagulopathies Severe Anaemia Hb less than 7 Endometrial Thickness greater than 15 mm

Design outcomes

Primary

Measure	Time frame
To reduce the PBAC (Pictorial Blood loss Assessment Chart) ScoreTimepoint: Baseline 1st Menstrual Cycle 2nd Menstrual Cycle 3rd Menstrual Cycle	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Shahzadi Sultana

Government Nizamia Tibbi College and General Hospital

drssntc@gmail.com9908624090

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026